The effect of unprocessed bran in a dose of 5 g three times daily and a dose of2.5 g three times daily for one year on the recurrence rate of anal fissures was studied in a double-blind, placebo-controlled trial in 90 patients with recently healed acute posterior anal fissures. Fifteen patients (16.6%) were withdrawn before the code was broken due to failure "to follow the trial protocol for various reasons. Significantly fewer recurrences occurred in patients receiving bran 5 g throe times daily (recurrence rate 16%, 95% confidence limits. 4.54 to 36.08) when compared with patients receiving bran 2.5 g three times daily (60%; 38.67 to 78.87) (P<0.01) and with patients receiving placebo three times daily (68%; 46.50 to 85.05) (P<0.01). No significant difference in recurrences was found between patients on bran 2.5 g and those on placebo.
Introduction
The majority of patients with an acute anal fissure complain about recurrent hard stools, and the avoidance of constipation and sphincter spasm seems to be an important element of conservative treatment.'. Although most acute anal fissures heal spontaneously or with conservative treatment, they tend to recur frequently", The problem of recurrent anal fissures due to hard stools might be avoided by dietary manipulation, whereby constipating foods are avoided and higher fibre food with increased amounts of fluids is encouraged.
A randomized controlled trial has been conducted in which the value of maintenance unprocessed bran in two different doses for one year was evaluated by comparing the recurrence rates in patients with recently healed acute posterior anal fissures.
Methods

Study population
Patients with recently healed first-episode acute posterior anal fissures caused by an episode of constipation were entered into the study. The fissures had initially been treated for 3 weeks with lignocaine ointment, hydrocortisone ointment, or warm sitz baths plus unprocessed bran, as described in detail elsewhere.'. There was no age limit.
Patients were excluded for the following reasons: if they initially had any signs of a chronic fissure; if they were taking bran or similar products prior to the initial treatment; if the initial fissures were thought to have other causes than constipation, e.g. diarrhoea, sexual truma or unknown causes; or if they were pregnant or had any signs of inflammatory bowel disease. plus bran intake Table 1 demonstrates that the three groups were well matched with regard to age, sex, and initial treatment of the healed fissures. There were no significant differences in these characteristics between the three treatment groups.
Study design
The double-blind study started on 1 June 1979 and ended on 30 November 1985. Treatment packs containing one year's supply of bran or placebo were centrally packaged. Sealed copies of the randomization schedule were held by an independent observer. Patients were entered immediately after treatment with one of the above mentioned conservative regimens if their fissures were healed. Each patient was randomized to one of the following treatments: unprocessed bran 5 g stirred into 200011 water and swallowed quickly three times daily in the morning, at lunch, and at bedtime; unprocessed bran 2.5 g mixed together with placebo 2.5 g (placebo: lactulose 80%, sucrose 17%, caramel 2.8%, and tartrazine 0.2%) stirred into 200011 water and swallowed quickly three times daily; or placebo 5 g stirred into 200011 water three times daily according to the same regimen.
Lactulose was chosen as part of the placebo diet since this disaccharide, like bran, is associated with excessive flatus, such that it would be impossible for the observer to identify the treatment regimens from the degree of flatus produced.
Treatment was continued for one year. All patients who completed the study were then followed up for a further six months. Treatment packs of 5 g were delivered to patients at the end of each month throughout the study period. The patients were clinically examined and had a proctological examination at three-month intervals or at any signs of recurrence. They were also questioned at each visit concerning side effects.
All patients were carefully told that the treatment could cause temporary flatulence and distension and that they should not stop taking their treatment packs on this account.
Statistical evaluation
Statistical evaluation was performed by Fisher's exact test or the Mann-Whitney U-test. P values of less than 0.05 were considered statistically significant. No power estimations were carried out before the investigation was started.
Patients withdrawn
Fifteen patients (16.6%) were withdrawn from the trial without knowledge of the treatment being given (5 from each treatment group). They comprised 3 patients with a previous diagnosis of colonic carcinoma (2 developed recurrence of their malignant disease and were admitted to hospital during the treatment period, and one died); 4 patients who were admitted to hospital for reasons other than anal fissure and were unable to follow the trial protocol; and 8 patients who refused to follow protocol after several months of treatment.
Compliance
Evaluation of pack consumption was based on diary cards. There was no difference between the treatment groups with regard to compliance, the group treated with bran 15 g daily taking 81.2% of the prescribed amount, the bran 7.5 g group taking 77%, and the placebo group taking 83.8%.
Eight patients (4 treated with bran 15 g, 3 with bran 7.5 g, and one with placebo) used laxatives during the study period but in such small amounts that they were not considered to have any effect on the recurrence rate.
Results
The bowel habits of patients before and after taking the bran and placebo diets are shown in Table 2 . Straining at st091 was used as a meaure of stool consistency. Bran in a dose of 15 g prevented straining at stool and changed the bowel habits significantly when compared to the placebo diet and bran in a dose of 7.5 g (P< 0.05). Figure 1 demonstrates the differences observed between the treatment groups. There were significantly fewer recurrent anal fissures within 12 months after treatment with unprocessed bran 15 g daily (recurrence rate 16%; 95% confidence limits, 4.54 to 36.08) compared to treatment with unprocessed bran 7.5 g daily (60%, 38.67 to 78.87) (P<O.OI) and placebo (60%; 46.50 to 85.05) (P<O.OI). No significant differences in the number of recurrences were found between placebo-treated patients and those treated with bran 7.5 g daily.
All recurrences in patients maintained on bran were without signs of a chronic fissure and they were all treated with the addition of warm sitz baths for 15 minutes after each bowel movement. In contrast, 9 of 17 recurrences among the placebo group had signs of a chronic fissure and were resistant to further conservative treatment; they were all cured by lateral subcutaneous internal aphincterotomy". Twenty-five percent of patients developed recurrent fissures within six months after maintenance therapy was stopped -7 (28%) in the bran 15 g daily group, 6 (24%)in the bran 7.5daily group, and 6 (24%) in the placebo group (NS).
Sixteen (64%) patients maintained on bran 15 g daily felt distended and passed more flatus during the initial treatment compared to 5 (20%) on bran 7.5g daily (P<0.05). Flatulence and distension disappeared within 10 weeks in all except 5 patients maintained on bran 15 g daily. In these 5 patients a sensation of slight distension and an increased tendency to pass flatus persisted throughout the 12-month study period, but they continued to take their bran as prescribed.
Discussion
This double-blind, placebo-controlled trial has demonstrated that unprocessed bran in a dose of 5 g three times daily reduces the recurrence rate of anal fissures in persons with healed first-episode acute posterior anal fissures in contrast to bran in a dose of 2.5 g three times daily.
The study has also demonstrated that recurrent fissures in patients maintained on bran, regardless of the employed dose, were amenable to conservative treatment, in contrast to recurrent fissures occurring in patients maintained on placebo in whom significantly more fissures were resistant to conservative treatment and required surgical therapy.
Our concept of the aetiology of anal fissure is to a large extent speculative. Previously reported data seem to support the general idea that trauma to' the anal canal during the passage of a hard stool is responsible for initiating the condition since acute anal fissures have been shown to heal quickly after the addition of unprocessed bran to the diet". That constipation also is a factor responsible for producing recurrent anal fissures is indirectly supported by the present findings. It is well established that unprocessed bran has a good effect on constipation", An important property of bran is that it can absorb four times its weight of water, and its effect in patients with recurrent anal fissure is probably related to the waterholding effect allowing a soft bulky stool to be passed more easily, causing a physiological dilatation of the anal sphincters.
Although the 'bran era' started in 1974 and it is widely held that a dietary intake rich in fibre is beneficial in preventing anal flssure", no randomized placebo-controlled studies have been published previously on the effect of maintenance bran or other bulk-forming agents in preventing anal fissures.
The present material can be characterized by its uniformity: all patients had recently healed, firstepisode, acute, posterior anal fissures with the same causative factor. Most other studies on anal fissures can be characterized by their complex material concerning localization of fissures, causative factors and number of patients with acute or chronic fissures. However, this study is open to criticism: many patients find unprocessed bran singularly unpalatable. Other fibre-containing agents might have been used, such as psyllium seed dietary fibres or bran compressed in tablet form4.~.
Ideally, the high-residue diet should consist of plenty of fresh fruit, vegetables, wholemeal bread and flour. However. such a diet is relatively expensive and cannot be afforded by all people. Unprocessed bran was used, since it is the cheapest way to add dietary fibre to the modern diet.
Unprocessed bran intake has also been shown to have beneficial effects on the symptoms of patients with diverticular disease and haemorrhoids, thereby avoiding the use of surgical procedures'"7. There are therefore many reasons for maintaining patients with anal and/or colorectal problems on bran or a high-fibre diet.
How long should maintenance therapy be continued? In an attempt to answer this question, the patients in this study were followed for a further six months after maintenance therapy was stopped. Twenty-five percent developed a recurrent fissure within this observation period. This rapid fissure recurrence rate has not been recorded previously and it seems likely that maintenance therapy with bran or preferably a high-fibre residue diet should be for life.
